Hosted by IDTechEx
Global Biotechnology Insights
Posted on June 12, 2019 by  & 

Funding for essential tremor therapy

Cala Health Inc, a bioelectronic medicine company developing wearable therapies for chronic disease, announced it has completed a $50 million Series C financing. Cala Health will use the funds to introduce Cala TrioTM, a breakthrough therapy for hand tremors in people with essential tremor, to the market as well as expand its therapeutic pipeline. For more information see the IDTechEx report on Bioelectronic Medicine 2019-2029.
 
New investors in the Series C financing include Novartis, Baird Capital, LifeSci Venture Partners, TriVentures, and others. All existing investors participated in the round, including Johnson & Johnson Innovation - JJDC, Inc. (JJDC), Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital, and GV.
 
"We are excited to continue partnering with Cala Health on its journey to support patients with chronic disease with wearable neuromodulation therapies," said Neil Tiwari, General Partner, dRx Capital, a Novartis & Qualcomm joint investment company.
 
Nicole Walker, General Partner at Baird, added "Cala Health is advancing neuromodulation therapy options without the need for surgery, using body- worn electronics. Baird is thrilled to invest in this field and in the company's future growth."
 
 
"We are delighted to work with such a strong team of investors and advisors who share our vision for the future of bioelectronic medicines. This financing follows exciting momentum from the past year, including receiving De Novo clearance from the Food and Drug Administration for our therapy for essential tremor and announcing a licensing agreement and ongoing collaboration with Partners Healthcare Innovation and its affiliate, Massachusetts General Hospital," said Kate Rosenbluth, PhD, Founder and CEO, Cala Health.
 
Cala Health is preparing for the limited release of the prescription Cala Trio therapy, including an innovative commercial strategy that delivers prescription therapy with the convenience of consumer electronics by serving the patients as a direct distributor. The company recently announced completing enrollment in the largest therapeutic study ever conducted in essential tremor in the US, the landmark PROspective study for SymPtomatic relief of Essential tremor with Cala Therapy (PROSPECT).
 
Source and top image: Cala Health Inc
Learn more at the next leading event on the topic: Healthcare Sensor Innovations USA 2020 External Link on 17 - 18 Mar 2020 at San Jose, USA hosted by IDTechEx.
More IDTechEx Journals